Fundraising Fox

Syncromune

Fort Lauderdale, US · Founded 2020 · Delaware corporation

syncromune.com ↗

Syncromune is developing SYNC-T, an in situ combination immunotherapy platform delivered directly into a target tumor to prompt the immune system to recognize and destroy cancer throughout the body. Its lead investigational therapy SV-102 is being evaluated in the LEGION-100 Phase 2 trial for metastatic castration-resistant prostate cancer.</parameter> <parameter name="founders">[]

BiotechHealthtech

Founders & leadership

JG
Joseph GerardiExecutive
SD
Stephen DaleExecutive
CJ
Charles J. LinkExecutive
KM
Kerri-Ann MillarExecutive
AG
Agustin GagoExecutive
EH
Eamonn HobbsNamed on SEC filing

Board

JL
Jeffrey L. ClelandBoard director
DG
Douglas G. WatsonBoard director
JC
Joseph C. MaroonBoard director
NS
Norman SchwartzBoard director

Reported raises · per SEC filings

Form D private placements

$159M disclosed across 2 rounds · 2022–2024

▶$144.8MraisedMay 2026 · 77 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph GerardiExecutive Officer
  • Jeffrey L. ClelandDirector
  • Douglas G. WatsonDirector
  • Joseph C. MaroonDirector
  • Stephen DaleExecutive Officer
  • Norman SchwartzDirector
  • Charles J. LinkExecutive Officer, Director
  • Eamonn HobbsExecutive Officer, Director
  • Kerri-Ann MillarExecutive Officer
  • Agustin GagoExecutive Officer
Offering amount
$144.8M
Amount sold
$144.8M
First sale
Dec 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14.2MraisedOct 2023 · 44 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph GerardiExecutive Officer
  • Norman SchwartzDirector
  • EAMONN HOBBSExecutive Officer, Director
  • AGUSTIN GAGOExecutive Officer
  • Douglas G. WatsonDirector
  • Jeffrey L. ClelandDirector
  • Charles J. LinkExecutive Officer, Director
  • Joseph C. MaroonDirector
Offering amount
$20M
Amount sold
$14.2M
First sale
May 2022
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap
Primmune Therapeutics17 shared keywordsPrimmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
Immunome13 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Adaptimmune10 shared keywordsAdaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
Immunomic Therapeutics9 shared keywordsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
Vaccinex9 shared keywordsVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.

Companies competing with Syncromune for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Syncromune do?
Syncromune is developing SYNC-T, an in situ combination immunotherapy platform delivered directly into a target tumor to prompt the immune system to recognize and destroy cancer throughout the body. Its lead investigational therapy SV-102 is being evaluated in the LEGION-100 Phase 2 trial for metastatic castration-resistant prostate cancer.</parameter> <parameter name="founders">[]
How much funding has Syncromune raised?
Syncromune has disclosed $159M raised across 2 rounds.
Where is Syncromune headquartered?
Syncromune is headquartered in Fort Lauderdale, US.